-       Drug Pipelines 
   - July 2023
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Report 
   - March 2023
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Report 
   - March 2023
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Report 
   - February 2023
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Drug Pipelines 
   - January 2023
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                   -       Drug Pipelines 
   - January 2023
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Drug Pipelines 
   - January 2023
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Drug Pipelines 
   - December 2022
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Drug Pipelines 
   - December 2022
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Drug Pipelines 
   - December 2022
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Drug Pipelines 
   - December 2022
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Report 
   - September 2022
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Report 
   - August 2022
    -  30 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                -       Report 
   - April 2023
    -  120 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - January 2024
    -  120 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - January 2022
    -  60 Pages 
    Global
   
   From       €2836EUR$3,160USD£2,489GBP 
      €3544EUR$3,950USD£3,111GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                -       Report 
   - December 2022
    -  83 Pages 
    Global
   
   From       €3141EUR$3,500USD£2,756GBP 
             
         The Kinase market is a subset of the Drug Discovery market, focusing on the development of drugs that target kinases, a type of enzyme that plays a role in many cellular processes. Kinase inhibitors are used to treat a variety of diseases, including cancer, diabetes, and neurological disorders. Kinase inhibitors are typically small molecules that bind to the active site of the kinase, blocking its activity.
Kinase inhibitors are developed through a combination of in vitro and in vivo assays, as    well as computational modeling. Companies in the Kinase market are focused on developing novel inhibitors that can be used to treat a variety of diseases. These companies include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less   Read more